August 2020

August 17, 2020

From the Editor-in-Chief, Evidence-Based Oncology, August 2020.

August 17, 2020

An agreement will tap Caris Life Sciences' next-generation sequencing technology to identify patients for Merus’ phase 1/2 eNRGy trial.

August 17, 2020

The challenges of complying with payer mandates in biosimilars were discussed in a webinar sponsored by The American Journal of Managed Care® and The Center for Biosimilars®.

August 17, 2020

Evidence-Based Oncology regulatory updates for August 2020 feature coverage of Kite Pharma's new CAR T-cell therapy and selinexor in DLBCL.

August 17, 2020

Evidence-Based Oncology managed care updates for August 2020 feature coverage of liquid biopsies, companion diagnostics, and CAR T-cell therapy.

August 16, 2020

Fewer off-target effects mean second-generation BTK inhibitors offer less cardiotoxicity and allow patients to stay on them longer, increasing their efficacy.

August 16, 2020

Proposed CMS rules would make it easier for state Medicaid programs to smooth the way for value-based contracts for high-cost gene therapies.

August 16, 2020

Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.

August 15, 2020

Clinical updates for August 2020 featured in Evidence-Based Oncology.

August 14, 2020

Better technology is rekindling the promise of DNA medicines in oncology, including the treatment of glioblastoma.

August 03, 2020

The ruling reversed a lower court ruling regarding the drug discount program for hospitals that serve patients covered by Medicaid.

August 02, 2020

A new treatment option is approved for patients with a common form of non-Hodgkin lymphoma who cannot have an autologous stem cell transplant.

July 01, 2020

Federal and state officials have implemented policies and safeguards to slow transmission of the virus. Most troubling were state moratoriums on “elective” surgical procedures.